VAERS reports by lot

Janssen (J&J) COVID-19 lot 206AZ1A: VAERS reports

26 VAERS reports list lot 206AZ1A as a Janssen (J&J) COVID-19 vaccine, received between 2021-04-13 and 2022-01-22. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
26
Reports
8%
Marked serious
0
With a death outcome
8
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)3426%
Neurological3225%
Musculoskeletal1411%
Gastrointestinal129%
Cardiac / Cardiovascular119%
Respiratory86%
Dermatological (non-injection-site)86%
Allergic / Anaphylactic32%
Psychiatric / Neuropsychiatric32%
Injection-site / Local reaction32%
Thrombotic / Hematological11%

Where reports came from

U.S. state of the reporter, where given (top 12).

Maryland5
Delaware3
California3
New Jersey3
Virginia3
Florida2
North Carolina1
New York1
Georgia1
Illinois1
Rhode Island1
Minnesota1

Reports by month received

2021-049
2021-053
2021-072
2021-085
2021-094
2021-111
2021-121
2022-011

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.